- Fee assured
- Awaiting verification
Dr Ashok Nikapota specialises in the treatment of urological cancer using radiotherapy, high dose rate brachytherapy (prostate cancer), chemotherapy and hormone therapy. He also has expertise in treating lymphoma and myeloma with radiotherapy.
He has extensive experience in the development and use of advanced radiotherapy techniques, including Intensity Modulated Radiotherapy (IMRT) and Image Guided Radiotherapy (IGRT). This enables delivery of shaped radiotherapy beams with daily imaging for accuracy, leading to reduced damage to surrounding structures with improved clinical outcomes. He is the Clinical Lead for radiotherapy and prostate brachytherapy at the Sussex Cancer Centre.
Dr Nikapota is responsible for the enrolment of patients into research studies evaluating new drugs in the treatment of cancer and the use of advanced radiotherapy techniques to improve outcomes and reduce treatment related side effects. He has authored a number of peer-reviewed publications. He is actively involved in the teaching, training and mentoring of undergraduate and postgraduate trainees.
Dr Nikapota undertook a Clinical Fellowship at Princess Margaret Hospital (Toronto) where he gained invaluable experience in advanced radiotherapy techniques. Prior to this he completed his Oncology training with placements at University College London Hospital, Mount Vernon Cancer Centre and the Royal Free Hospital.
Outside work, Dr Nikapota enjoys spending time with his young family. He is a keen classical musician, both playing and listening to orchestral and chamber music
Areas of interest
Urological oncology; Lymphoma
Current NHS consultant posts held
Consultant Clinical Oncologist Sussex Cancer Centre and Worthing and Southlands Hospital
- MBBS University of London 1998
- MRCP Royal College of Physicians 2003
- FRCR Royal College of Radiologists 2006
Reference number 4477947
Details of entry to specialist register
- Clinical Oncology CCST, 2008
Affiliations / memberships
British Uro-Oncology Group
NCRI Bladder Cancer (TABS) Subgroup